Cancer News and Research

Latest Cancer News and Research

ChromoCure announces interim stockholder guidance on upcoming events

ChromoCure, Inc. announced today interim stockholder guidance on upcoming events. Full details on the below items will be released in the coming days.

9 Jan 2010

Biomarker may enable personalized GVHD treatment for bone marrow transplant patients

University of Michigan researchers have identified the first biomarker of graft-versus-host disease of the skin. The discovery makes possible a simple blood test that should solve a treatment dilemma facing doctors with patients who frequently develop rashes after bone marrow transplants.

9 Jan 2010

Ochsner Health System to acquire NSRMC

The private, not-for-profit Ochsner Health System today announced the signing of a definitive agreement to purchase NorthShore Regional Medical Center (NSRMC), the ambulatory surgery center and several pieces of property on which the facility is located in Slidell, Louisiana. The projected closing date is April 1, 2010: this purchase will expand Ochsner Health System to eight hospitals in Southeast Louisiana. The medical staff will remain "open," which is consistent with how the facility operates today.

9 Jan 2010

FDA yet to review MannKind’s NDA for insulin therapy

MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind’s new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.

9 Jan 2010

Plexxikon commences dosing in PLX4032 Phase 3 trial for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 “BRAF Inhibitor in Melanoma” (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.

9 Jan 2010

Cancer Research UK scientists named on New Year's Honours list

Several of Cancer Research UK's scientists have been named on this year's New Year's Honours list, as has the government's National Cancer Director and a long-term supporter of the charity.

9 Jan 2010

R. Palmer Beasley awarded Hepatitis B Foundation's Distinguished Scientist Award 2010

R. Palmer Beasley, M.D., Ashbel Smith Professor at The University of Texas School of Public Health, has been awarded the Hepatitis B Foundation's Distinguished Scientist Award 2010.

9 Jan 2010

Green Cross seeks regulatory approval for peramivir in S.Korea

BioCryst Pharmaceuticals, Inc. today announced that it has been informed by its partner, Green Cross Corp., that Green Cross has filed a New Drug Application (NDA) in South Korea to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza.

9 Jan 2010

St. Andrews Country Club hosts 'Morgan & Friends Fight Cancer' Tournament to help fight breast cancer

St. Andrews Country Club of Boca Raton members teamed up with LPGA Tour player Morgan Pressel this week to raise $405,000 through the 3rd annual 'Morgan & Friends Fight Cancer' Tournament to help fight breast cancer through early detection and treatment.

9 Jan 2010

Genentech's ACTEMRA approved to treat RA

Genentech, Inc., a wholly owned member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

8 Jan 2010

TetraLogic Pharmaceuticals commences its TL32711 SMAC mimetic Phase 1 clinical trial

TetraLogic Pharmaceuticals announced today that the Company has completed dosing of the first cohort in a Phase 1 clinical trial of its selective SMAC mimetic, TL32711. The Phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study will also assess the pharmacokinetics, pharmacodynamics and anti-tumor activity of TL32711.

8 Jan 2010

Synta Pharmaceuticals announces pricing of public offering of shares

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the pricing of an underwritten public offering of 5,555,556 shares of its common stock at a price to the public of $4.50 per share for gross proceeds of approximately $25 million.

8 Jan 2010

John C. Lechleiter to deliver keynote address on human dimensions of medical innovation

John C. Lechleiter, PhD, Chairman, President & CEO, Eli Lilly and Company, will deliver a keynote address, "Lifespans and Livelihoods: The Human Dimensions of Medical Innovation," to TOWN HALL Los Angeles on Thursday, January 14, 2010 at the Millennium Biltmore Hotel.

8 Jan 2010

Seminar highlights latest treatment options for common medical conditions that affect men

Dr. Y. Mark Hong, with Affiliated Urologists, a specialist in men's health issues, will be leading a free Men's Health Seminar on Thursday, January 21st. The program, to be held at 5:00 pm at the Moon Valley Country Club, will explain the latest treatment options for one of the most common conditions affecting men today: Benign Prostate Hyperplasia (also known as Enlarged Prostate). A question and answer period will follow the program.

8 Jan 2010

ESF-UB Conference to concentrate on potentially clinically relevant polymorphisms

Pharmacogenetics started in the fifties with the discovery of primaquine-related haemolysis among glucose-6-phosphate deshydrogenase deficient patients. At the end of the century, it progressively evolved into Pharmacogenomics, investigating simultaneously multiple gene targets till covering the whole genome in relation with altered drug response.

8 Jan 2010

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the 725th event (patient death) has been reached in its pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy.

8 Jan 2010

Access Pharmaceuticals completes enrollment for Prolindac monotherapy trail, begins combination study

ACCESS PHARMACEUTICALS, INC., today announced that it has completed enrollment and evaluation of the last additional cohort of patients in the ongoing clinical study of ProLindac as a monotherapy in ovarian cancer patients who have received at least two prior platinum based treatment regimens.

8 Jan 2010

Canadian Cancer Society calls on the B.C. government to ban cosmetic use of pesticides

The Canadian Cancer Society British Columbia and Yukon today called on the B.C. government to enact legislation to ban the cosmetic use of pesticides that would set a new national standard. The Society is also asking British Columbians to participate in the on-line public consultation.

8 Jan 2010

Use of technology that expands access to qualified radiologist leads to earlier diagnosis and treatment of breast cancer

Use of technology that expands access to the most qualified radiologist will lead to earlier diagnosis and treatment of breast cancer, said MedSolutions, a leading provider of medical cost management services.

8 Jan 2010

Subjective cognitive impairment in healthy older adults can increase risk for dementia

Forgot where you put your car keys? Having trouble recalling your colleague's name? If so, this may be a symptom of subjective cognitive impairment (SCI), the earliest sign of cognitive decline marked by situations such as when a person recognizes they can't remember a name like they used to or where they recently placed important objects the way they used to.

8 Jan 2010

Cancer News and Research

Latest Cancer News and Research

ChromoCure announces interim stockholder guidance on upcoming events

Biomarker may enable personalized GVHD treatment for bone marrow transplant patients

Ochsner Health System to acquire NSRMC

FDA yet to review MannKind’s NDA for insulin therapy

Plexxikon commences dosing in PLX4032 Phase 3 trial for metastatic melanoma

Cancer Research UK scientists named on New Year's Honours list

R. Palmer Beasley awarded Hepatitis B Foundation's Distinguished Scientist Award 2010

Green Cross seeks regulatory approval for peramivir in S.Korea

St. Andrews Country Club hosts 'Morgan & Friends Fight Cancer' Tournament to help fight breast cancer

Genentech's ACTEMRA approved to treat RA

TetraLogic Pharmaceuticals commences its TL32711 SMAC mimetic Phase 1 clinical trial

Synta Pharmaceuticals announces pricing of public offering of shares

John C. Lechleiter to deliver keynote address on human dimensions of medical innovation

Seminar highlights latest treatment options for common medical conditions that affect men

ESF-UB Conference to concentrate on potentially clinically relevant polymorphisms

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

Access Pharmaceuticals completes enrollment for Prolindac monotherapy trail, begins combination study

Canadian Cancer Society calls on the B.C. government to ban cosmetic use of pesticides

Use of technology that expands access to qualified radiologist leads to earlier diagnosis and treatment of breast cancer

Subjective cognitive impairment in healthy older adults can increase risk for dementia

Cancer Research - Second Edition eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in